Testing a new medicine for healthy adults
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests a new medicine called ATI-105 in healthy adults to see if it is safe and how the body handles it. If you are generally healthy, you might be able to participate and help researchers learn more about this potential treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You are in good overall health (no major illnesses).
- Your body mass index (BMI) is between 18 and 35.
- You can swallow capsules.
- If you or your partner can have children, you must use effective birth control during the study.
- You are not pregnant or breastfeeding.
- You have not used any prescription or over-the-counter medications, herbal products, or supplements recently (except stable thyroid medication).
- You have not used GLP-1 agonist medicines (like Ozempic or Wegovy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called DT-216P2 in healthy people to find a safe dose. It is a first step in developing a treatment for Friedreich ataxia, a genetic condition that affects movement and balance.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
This study looks at how heart disease progresses in people with Friedreich's ataxia, a genetic condition that affects coordination and heart health. By taking part, you help researchers better understand the condition, which may guide future treatments.
This trial tests a one-time gene therapy called LX2006 for heart problems caused by Friedreich ataxia. The goal is to see if it can improve heart function and structure.
This study tests a new medicine called NNC0705-0002 in healthy volunteers to see if it is safe and how the body handles it. It helps find the right dose for future studies.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.